PRL2 inhibition, therefore, provides a mechanism and potential therapeutic strategy to elevate the level of PTEN protein, attenuate hyperactivated AKT signaling, and rescue the AML phenotype. Here, PTP4A2 is linked to acute myeloid leukemia.